A comprehensive view of American Society of Hematology (ASH). This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
Bristol Myers Squibb presents two early studies evaluating potential first-in-class oral CELMoD agent Golcadomide for the treatment of non-hodgkin lymphomas at ASH 2023
Published:
December 11, 2023
by Bristol-Myers Squibb Co.
|
Bristol Myers Squibb announces updated results from three key multiple myeloma research programs at ASH 2023; the programs include CAR T BMS-986393, CELMoD agent mezigdomide and the T cell engager alnuctamab
Published:
December 11, 2023
by Bristol-Myers Squibb Co.
|
Pfizer’s experimental injectable drug, marstacimab, shows positive results in reducing bleeding episodes for hemophilia A and B patients; Phase 3 results presented at the annual meeting for the American Society of Hematology
Published:
December 11, 2023
by MedCityNews.com
|
New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Published:
December 11, 2023
by F. Hoffmann-La Roche Ltd. (Roche)
|
Bristol Myers Squibb presents new data at ASH 2023 demonstrating clinical benefit across B-cell malignancies with Breyanzi as a second-line treatment in high-risk follicular lymphoma and in relapsed or refractory chronic lymphocytic leukemia
Published:
December 10, 2023
by Bristol-Myers Squibb Co.
|
Ask us about our Health Care Sector market view